Avidity Partners Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Avidity Partners Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-214,400	Closed	-$4.04M	–	42
2025 Q3	$4.04M	Sell	214,400 -53,600	-20%	-$845K	0.92%	28
2025 Q2	$3.76M	Buy	+268,000	New	+$3.76M	0.75%	37
2023 Q2	–	Sell	-1,628,500	Closed	-$17.9M	–	95
2023 Q1	$17.9M	Sell	1,628,500 -126,500	-7%	-$1.83M	0.59%	53
2022 Q4	$26M	Buy	1,755,000 +960,500	+121%	+$16.8M	0.56%	46
2022 Q3	$15.2M	Buy	+794,500	New	+$18M	0.31%	59

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avidity Partners Management's ARQT Position: Q4 2025 in Review

Avidity Partners Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 214,400 shares — an estimated $4.04M sold.

Avidity Partners Management first reported a position in ARQT in Q3 2022 and held it in 5 quarters. The position peaked at $26M in Q4 2022. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

Avidity Partners Management reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
Avidity Partners Management sold 214,400 Arcutis Biotherapeutics shares in Q4 2025, an estimated $4.04M.
Avidity Partners Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 5 quarters.
Avidity Partners Management's Arcutis Biotherapeutics position peaked at $26M in Q4 2022.
283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.